Background: Previous studies have shown that polycystic ovary syndrome is a predictor of gestational diabetes mellitus, but we do not know exactly how many polycystic ovary syndrome patients may develop gestational diabetes mellitus. Currently, the incidence of gestational diabetes mellitus among women with polycystic ovary syndrome varies greatly across studies, ranged from 4.12% to 59.50%. Besides, many factors have been found to be related to the incidence of gestational diabetes mellitus among women with polycystic ovary syndrome, but the results among different studies are not consistent. The possible causes of inconsistencies between the current estimates were unclear. This review aimed at exploring the pooled incidence of gestational diabetes mellitus among women with polycystic ovary syndrome, summarizing possible causes of the inconsistencies in the current estimates, try to provide a reference for prevention of gestational diabetes mellitus and polycystic ovary syndrome in the future. Methods: Systematic searches of different databases (including EMBASE, Web of Science, MEDLINE, The Cochrane Library, CNKI and PubMed) were conducted for studies published until 31 May 2021. Statistical analyses were performed using R software, the pooled incidence of gestational diabetes mellitus among polycystic ovary syndrome patients was combined using random effects model. Cochrane’s “Tool to Assess Risk of Bias in Cohort Studies” was used for quality assessment. Results: Twenty-two longitudinal studies were included. A total of 24,574 women with polycystic ovary syndrome were identified in the 22 articles, of which 4478 were reported with gestational diabetes mellitus. The pooled incidence of gestational diabetes mellitus among women with polycystic ovary syndrome was 20.64%, with a 95% CI of 14.64% to 28.30%. In the meta-regression model, several variables including age, area, quality score and sample size were suggested as significant sources of heterogeneity, accounted for 77.57% of the heterogeneity across studies. Conclusions: Evidence in this review suggests that gestational diabetes mellitus were common among women with polycystic ovary syndrome. More research is needed to found effective interventions for preventing gestational diabetes mellitus among women with polycystic ovary syndrome.

Neurodegenerative diseases (NDDs) are a group of disorders characterized by the progressive loss of neurons in specific areas of the central nervous system. In recent years, more and more research has focused on the influence of diet on NDDs. As a common food, processed red meat is widely consumed worldwide. Many studies have shown that processed red meat may increase the risk of cancer, diabetes and cardiovascular disease. Unfortunately, it is unclear whether processed red meat affects NDDs. Therefore, we reviewed the existing literature on the role of processed meats in NDDs. We concluded that intake of processed meat may have an adverse effect on NDDs.

Brucellosis is a prevalent zoonotic infectious disease that poses a significant public health concern. The economic burden of human brucellosis includes hospitalization costs, pharmacological treatment, out-of-pocket expenses, and income loss due to missed work during illness. This case report describes recurrent seizures resulting from drug interactions in a patient undergoing treatment for brucellosis. Although rifampicin-based regimens are the first-line treatment for brucellosis, rifampicin is a potent inducer of various drug-metabolizing enzymes and can interact with numerous medications, including antiepileptic drugs. Alternative anti-Brucella agents may be considered when drug interactions are of concern. The choice of antiepileptic therapy should aim to minimize potential interactions with rifampicin. If such interactions are unavoidable, co-administration should be closely managed using therapeutic drug monitoring to prevent subtherapeutic dosing, seizure recurrence, or compromised brucellosis treatment efficacy. In this case, rifampicin was replaced with an alternative anti-Brucella agent to minimize interaction risks, and antiepileptic drug dosages were optimized using therapeutic drug monitoring to achieve seizure control. Patient education on medication adherence was also reinforced to support treatment outcomes.

Objective: Oxazolidinone antibiotics are mainly used for skin and soft tissue infections,sepsis,bone marrow inflammation and other diseases caused by Gram-positive bacteria. Despite the emergence of oxazolidinones as a preferred treatment for drug-resistant Gram-positive bacterial infections, there remains a scarcity of large-scale, real-world studies assessing their safety profiles. The purpose of this study is to determine the adverse events of oxazolidinone antibiotics in the real world environment by analyzing the data of oxazolidinone antibiotics. Method: A retrospective analysis was conducted using reports of adverse drug events (ADEs) extracted from the WHO-VigiAccess database. The significant associations between oxazolidone antibacterial agents and ADEs were evaluated using an imbalance analysis that incorporated reported odds ratios (ROR) and proportional reporting rates (PRR). Result: The investigation unveiled 35,750 linezolid-related adverse event (AE) reports and 608 tedizolid-related AE from the WHO-VigiAccess database.The analysis of the top 30 reported preferred terms (PTs) involving both drugs revealed several key adverse reactions, including thrombocytopenia, anemia, pancytopenia, decreased platelet count, neutropenia, peripheral neuropathy, serotonin syndrome, blurred vision, pruritus, dyspnea, nausea, vomiting, rash, diarrhea, dizziness, and headache. These findings are consistent with reports on adverse reactions associated with drugs used in the treatment of mitochondrial diseases, as detailed in recent studies.These adverse reactions encompassed 27 system organ classifications (SoCs), with a primary focus on blood and lymphatic system disorders, nervous system disorders, and general disorders or administration site conditions. Conclusion: This study provides a detailed report on the levels of SOC and specific PT associated with oxazolidinone antibiotics, highlighting the need for vigilance regarding serious adverse events caused by these drugs. Furthermore, attention should be paid to the hematological and nervous system toxicity associated with oxazolidinone drugs. Our findings offer valuable insights into optimizing the use of oxazolidinone antibacterial drugs and minimizing potential side effects. It is expected to promote the safe use of oxazolidinone antibacterial drugs in the clinical environment.